Recruiting PHASE2 INTERVENTIONAL 1-arm NCT06516445

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

A Clinical Study of Short Course Radiotherapy (SCRT) Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer

Sponsor: Huazhong University of Science and Technology

Conditions Colorectal Cancer

Interventions CAPEOX Camrelizumab Fluzoparib SCRT

Updated 2 times since 2024 Last updated: Jul 18, 2024 Started: Jun 28, 2023 Primary completion: Jun 28, 2025 Completion: Jun 28, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Colorectal Cancer, this trial is actively recruiting participants. The trial is conducted by Huazhong University of Science and Technology and has accumulated 2 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

2 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2

First recorded

Jun 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Huazhong University of Science and Technology

Data source: Huazhong University of Science and Technology

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China